Martingale Asset Management L P lessened its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) by 60.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,918 shares of the biopharmaceutical company's stock after selling 46,518 shares during the quarter. Martingale Asset Management L P owned 0.05% of Vanda Pharmaceuticals worth $339,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. CI Investments Inc. purchased a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at about $107,000. Massachusetts Financial Services Co. MA increased its holdings in Vanda Pharmaceuticals by 1.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 151,389 shares of the biopharmaceutical company's stock valued at $1,712,000 after buying an additional 1,554 shares during the last quarter. State of Tennessee Treasury Department increased its holdings in Vanda Pharmaceuticals by 13.7% during the first quarter. State of Tennessee Treasury Department now owns 36,955 shares of the biopharmaceutical company's stock valued at $418,000 after buying an additional 4,442 shares during the last quarter. JPMorgan Chase & Co. raised its position in Vanda Pharmaceuticals by 4.8% in the first quarter. JPMorgan Chase & Co. now owns 363,768 shares of the biopharmaceutical company's stock worth $4,114,000 after acquiring an additional 16,716 shares during the period. Finally, WINTON GROUP Ltd boosted its stake in shares of Vanda Pharmaceuticals by 35.3% during the 1st quarter. WINTON GROUP Ltd now owns 77,123 shares of the biopharmaceutical company's stock worth $872,000 after acquiring an additional 20,101 shares during the last quarter. Institutional investors own 99.42% of the company's stock.
Get Vanda Pharmaceuticals alerts:Insider Buying and Selling at Vanda Pharmaceuticals
In other news, Director Stephen Ray Mitchell sold 2,700 shares of the stock in a transaction on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the completion of the sale, the director now directly owns 6,515 shares of the company's stock, valued at $61,762.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CMO Joakim Wijkstrom sold 3,605 shares of the stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $10.27, for a total transaction of $37,023.35. Following the completion of the sale, the chief marketing officer now owns 96,673 shares in the company, valued at $992,831.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen Ray Mitchell sold 2,700 shares of the business's stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $9.48, for a total value of $25,596.00. Following the completion of the transaction, the director now directly owns 6,515 shares in the company, valued at $61,762.20. The disclosure for this sale can be found here. Insiders have sold 8,544 shares of company stock valued at $87,181 over the last 90 days. 7.00% of the stock is currently owned by corporate insiders.
Vanda Pharmaceuticals Trading Down 4.0 %
Shares of NASDAQ:VNDA opened at $10.38 on Tuesday. The stock has a 50 day moving average of $10.83 and a 200 day moving average of $10.89. The company has a market cap of $587.09 million, a PE ratio of 51.90 and a beta of 0.47. Vanda Pharmaceuticals Inc. has a 12-month low of $9.24 and a 12-month high of $21.44.Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, June 3rd.
About Vanda Pharmaceuticals
(Get Rating)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Read More
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- MarketBeat Podcast: Stock Market, Bad News is Good News
- Forget Bitcoin, Block's Ecosystems are the Real Growth Drivers
- What Does an Inverted Yield Curve Mean For You?
- SPY vs. QQQ: Which ETF Wins in 2022?
- Could Snap Stock Rebound As Management Restructures?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.